EBITDA sell-side analyst consensus figures

19 May 2025

The consensus figures are based on analysts’ estimates recorded by the Company. The below consensus figures represent the aggregated expectations of sell-side analysts who, to the best of our knowledge, cover Aperam on a continuous basis.

The analysts listed below follow Aperam on their own initiative and Aperam is not responsible for their views.

Adj. EBITDA consensus estimates

PeriodNumber of sell-side
analysts participation		Adj. EBITDA consensus average 
Q2-20256 Average: EUR 125 million
Range: EUR 109 – 127 million

* Data as of 19 May 2025

The sell-side consensus is compiled from updated and maintained  forecasts from the analysts named below:

  • Alphavalue (does not provide quarterly estimates)
  • Barclays
  • Citigroup
  • Degroof Petercam
  • Deutsche Bank
  • Exane BNP Paribas
  • ING
  • JP Morgan
  • KeplerCheuvreux
  • Morgan Stanley
  • Oddo BHF
Disclaimer

The consensus figures are based on estimates, forecasts and predictions made by third party financial analysts and can only be seen as a consensus view on Aperam’s results from an outside perspective. Aperam does not accept any responsibility for the quality or accuracy of forecasts or estimates. This web page may contain forward-looking statements based on current assumptions and forecasts made by Aperam or third parties. Various known and unknown risks, uncertainties and other factors could lead to material differences between Aperam’s actual future results, financial situation, development or performance, and the estimates given here. These factors include those discussed in Aperam’s periodic reports available on www.aperam.com, section Investors & Shareholders.